×
For best experience we recommend to activate Javascript in your browser.
Recombinant FAP (Sibrotuzumab Biosimilar) antibody
The Human Monoclonal anti-FAP (Sibrotuzumab Biosimilar) antibody (ABIN7675741) specifically detects FAP (Sibrotuzumab Biosimilar) in BLI, ELISA, FACS, Func and SPR.
The antibody is reactive with Human samples.
Catalog No. ABIN7675741
$346.15
Plus shipping costs $50.00
1 mg ABIN7581401
100 μg ABIN7675741
1 mg ABIN7581401
100 μg ABIN7675741
Delivery in 10 to 12 Business Days
Quick Overview for Recombinant FAP (Sibrotuzumab Biosimilar) antibody (ABIN7675741)
Target
FAP (Sibrotuzumab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
All hosts for FAP (Sibrotuzumab Biosimilar) antibodies
Human
Clonality
All clonalities for FAP (Sibrotuzumab Biosimilar) antibodies
Monoclonal
Conjugate
All conjugates for FAP (Sibrotuzumab Biosimilar) antibodies
This FAP (Sibrotuzumab Biosimilar) antibody is un-conjugated
Application
Bio-Layer Interferometry (BLI), ELISA, Flow Cytometry (FACS), Functional Studies (Func), Surface Plasmon Resonance (SPR)
Product Details anti-FAP (Sibrotuzumab Biosimilar) Antibody
(hide)
Expression System
CHO Cells
Purpose
Anti-FAP Reference Antibody (sibrotuzumab)
Characteristics
Anti-FAP Reference Antibody (sibrotuzumab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
Purity
>95 %
Isotype
IgG1
Alternatives
(show)
Application Details
(hide)
Application Notes
Optimal working dilution should be determined by the investigator.
Restrictions
For Research Use only
Handling
(hide)
Format
Lyophilized
Concentration
1 mg/mL
Buffer
25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
Storage
4 °C,-80 °C
Storage Comment
+4°C,-80°C
Target Details for FAP (Sibrotuzumab Biosimilar)
(hide)
Target
FAP (Sibrotuzumab Biosimilar)
Target Type
Biosimilar
Molecular Weight
145.5 kDa
UniProt
Q12884
Recently viewed
(hide)
You are here:
Homepage
Recombinant anti-FAP (Sibrotuzumab Biosimilar) antibody (ABIN7675741)
Chat with us , powered by LiveChat